AzTrials
AzTrials

StrokeVAMMPRISNCT02506907

Characterizing Hemodynamic Compensation in Patients With Intracranial Stenosis

An observational study of Stroke and Intracranial Stenosis, run by Vanderbilt University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The overall aim of this work is to assess the relationship between stroke risk and hemodynamic compensation strategies, as measured using a novel 3.0 Tesla MRI protocol, in patients with symptomatic intracranial (IC) steno-occlusive disease. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Stroke, Intracranial Stenosis
How many people
63 participants
Where
1 siteUnited States
Study dates
Aug 2012to 1 Nov 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with intracranial stenosis who have had a stroke within the past 60 days

Who may be able to join

  • Adult patients (age 18-85, inclusive)
  • Symptomatic (TIA or ischemic stroke) in the hemispheric carotid territory of vascular stenosis
  • Vascular imaging demonstrating large vessel IC stenosis>50% or occlusion of IC carotid or MCA
  • Sub-acute stroke patients who have received intravenous or intra-arterial treatments
  • Sub-acute stroke patients ineligible for conventional acute stroke intervention. Language comprehension intact, motor aphasia mild or absent, competent to give informed consent
  • Most recent qualifying TIA or stroke within 60 days prior to performance date of hemodynamic MRI

Who cannot join

  • ECA stenosis > 70% determined by MRA, CTA, or DSA.
  • Acute stroke patients presenting with anterior circulation stroke onset eligible for intervention with intra-arterial thrombolysis or mechanical thrombectomy
  • MRI contraindications (e.g. non-compatible implants, pregnancy, etc.)
  • Non-atherosclerotic cervical or intracranial stenosis
  • Heart disease likely to cause cerebral ischemia, including cardiomyopathy with ejection fraction<25%, prosthetic valve, infective endocarditis, sick sinus syndrome, myxoma, left atrial or ventricular thrombus
  • Existing condition likely to lead to death within 2 years

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232

Other trials in United States

About this study

Official title: Vanderbilt Assessment of Multi-modal MRI in Patients At-Risk for Stroke With Intracranial Stenosis

The overall aim of this work is to assess the relationship between stroke risk and hemodynamic compensation strategies, as measured using a novel 3.0 Tesla MRI protocol, in patients with symptomatic intracranial (IC) steno-occlusive disease. Recent studies have shown high two-year ischemic stroke rates in symptomatic patients with IC arterial stenosis. Therapy for IC stenosis patients includes revascularization with angioplasty, IC stenting, or bypass, however identification of patients most likely to benefit from these more aggressive interventions, rather than medical management alone, has been problematic. Accurate measurements of hemodynamic compromise are likely required to better define stroke risk and guide treatment decisions. Specifically, in IC stenosis patients with compromised cerebral perfusion pressure (CPP), the extent of hemodynamic compromise reflects the autoregulatory capacity of vasculature to increase arterial cerebral blood volume (aCBV) and/or develop collaterals to supplement cerebral blood flow (CBF). The prevalence of CBF collateralization and aCBV autoregulation has been hypothesized to correlate uniquely with stroke risk, however the extent of this correlation has been debated. The critical barrier to stratifying stroke risk rests with a lack of (i) methodology for measuring multiple hemodynamic factors with high specificity and (ii) noninvasive approaches capable of monitoring longitudinal progression of impairment. The investigators have demonstrated the clinical utility of relatively new, noninvasive MRI approaches for assessing cerebrovascular reactivity (CVR), aCBV, and collateral CBF. The investigators hypothesize that stroke risk can be more completely evinced from collective measurements of these parameters. Therefore, the investigators propose to implement a novel, validated hemodynamic MRI protocol to assess tissue-level impairment and compensation strategies in patients with IC stenosis. Using a collective approach combining measurements of collateral CBF, aCBV and CVR in multiple brain regions, in conjunction with a statistical model incorporating the above variables as possible prognostic factors, the investigators will quantify the extent to which two-year stroke risk is associated with hemodynamic compensation mechanisms. The noninvasive and multi-faceted scope of this investigation is intended to expand the diagnostic stroke infrastructure and elucidate new hemodynamic prognostic indicators of stroke in this high-risk population.

Read the detailed description

The overall aim of this work is to assess the relationship between stroke risk and hemodynamic compensation strategies, as measured using a novel 3.0 Tesla (T) MRI protocol, in patients with symptomatic intracranial (IC) steno-occlusive disease. Recent studies have shown high two-year ischemic stroke rates of approximately 20% in symptomatic IC stenosis patients. Aggressive therapy for IC stenosis patients includes revascularization with angioplasty, IC stenting, or bypass, however identification of patients most likely to benefit from these more aggressive interventions, rather than medical management alone, has been problematic. Accurate measurements of hemodynamic compromise are likely required to better define stroke risk and guide treatment decisions. Specifically, in IC stenosis patients with compromised cerebral perfusion pressure (CPP), the extent of hemodynamic compromise reflects the autoregulatory capacity of vasculature to increase arterial cerebral blood volume (aCBV) and/or develop collaterals to supplement cerebral blood flow (CBF). The prevalence of CBF collateralization and aCBV autoregulation has been hypothesized to correlate uniquely with stroke risk, however the extent of this correlation is debated.

The critical barrier to stratifying stroke risk rests with a lack of (i) methodology for measuring multiple hemodynamic factors with high specificity and (ii) noninvasive approaches capable of monitoring longitudinal progression of impairment. The investigators have demonstrated the clinical utility of relatively new, noninvasive MRI approaches for assessing cerebrovascular reactivity (CVR), aCBV, and collateral CBF. These approaches have been optimized and feasibility assessed in healthy volunteers or isolated clinical studies, however comparatively little information is available regarding the relationship between these collective measures and stroke risk. Therefore, the investigators propose to complement established angiographic and structural imaging with more novel, validated hemodynamic measurements to assess tissue-level impairment and compensation strategies in patients with IC stenosis. Using a collective approach combining measurements of collateral CBF, aCBV and CVR in multiple brain regions, in conjunction with a statistical model incorporating the above parameters as possible prognostic factors, the investigators will quantify the extent to which two-year stroke risk is associated with hemodynamic compensation mechanisms in a population of symptomatic IC stenosis patients. The noninvasive and multi-faceted scope of this investigation is intended to expand the diagnostic stroke infrastructure and elucidate new hemodynamic prognostic indicators of stroke in this high-risk population.

Hypothesis (1). Changes in collateral CBF with hypercarbic stimulation positively correlate with two-year stroke incidence in symptomatic IC stenosis patients.

Aim (1). By separately magnetically labeling blood water in different feeding arteries (8), the investigators will use a tested vessel-selective arterial spin labeling (VS-ASL) approach and a calculated perfusion asymmetry index to noninvasively assess changes in collateral CBF patterns in patients with IC stenosis. IC stenosis (n=90) patients will be monitored for two years during which their known stroke incidence is 20%. Stroke incidence will be recorded and separate correlations between perfusion asymmetry and stroke risk will be assessed.

Hypothesis (2). Regionally reduced CVR, indicative of vascular steal phenomena, and elevated aCBV, will positively correlate with two-year stroke incidence in symptomatic IC stenosis patients.

Aim (2). CVR, as measured using the blood oxygenation level-dependent (BOLD) MRI signal change in response to hypercarbia, will be used to assess cerebrovascular reserve. The inflow vascular-space-occupancy with dynamic subtraction (iVASO-DS) approach, which we have developed and demonstrated in patients, will be applied to assess baseline aCBV. For the same patients as in Aim 1, CVR dynamics and aCBV will be statistically assessed for unique relationships with two-year stroke incidence.

Hypothesis (3). Collateral CBF, autoregulatory aCBV, and CVR will correlate unequally with two-year stroke incidence, the extent of which can be quantified using a multi-component prediction model.

Aim (3). The investigators will build a statistical prediction model, using collateral CBF, aCBV and CVR as prognostic factors, to quantify the extent to which trends in the above parameters collectively contribute to stroke risk. The high two-year stroke rate (20%) and large number of admitted patients with symptomatic IC stenosis, will enable this study to detect hypothesized group differences with high statistical power.

This work is an extension of recent methodological work whereby a novel, collective compensatory hemodynamic protocol is applied to a specific clinical population to understand prognostic potential. Successful completion should provide new information on tissue hemodynamics and stroke risk in patients that can be used to guide management decisions, ultimately reducing stroke incidence in this high-risk population.

Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02506907
Study groupRoleWhat they receive
AtheroscleroticPatients with atherosclerotic intracranial stenosis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Stroke

    An overt or silent stroke (on MRI) in two years

    Measured: Two years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jul 2015 (estimated)
  2. Study startAug 2012
  3. Primary completion6 Jun 2016
  4. Study completion1 Nov 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
63 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02506907
Sponsor's protocol ID
VUMC-VAMMPRIS
Acronym
VAMMPRIS
Status last verified
Jan 2018
First submitted
21 Jul 2015
Last updated
25 Jan 2018
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Stroke and Intracranial Stenosis, run by Vanderbilt University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Stroke (time frame: Two years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in